 |
|
|
|
|
|
|
|
 |
Results for 'Kinases' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Kinase Inhibitors
|
January 2006 |
£2410 |
74 % |
Strategic Outlook on Protein Kinase Inhibitors in Oncology
|
February 2006 |
£1325 |
71 % |
Analytical Tool: Protein Kinase Inhibitors in Oncology
|
February 2006 |
£2105 |
71 % |
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
|
November 2007 |
£2495 |
70 % |
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology
|
August 2006 |
£2340 |
69 % |
Protein Kinase Inhibitors in Oncology: Drug Pipeline Update 2006
Drug Pipeline Update 2007
|
May 2007 |
£1015 |
69 % |
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
|
May 2006 |
£2340 |
68 % |
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents
|
October 2006 |
£2340 |
67 % |
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology
|
December 2006 |
£3510 |
63 % |
Kinase Screening & Profiling Trends 2008
|
May 2008 |
£1540 |
30.8 % |
Lead Optimization Strategies
An analysis of novel molecular targets to develop innovative new therapeutics
|
January 2005 |
£1495 |
18.55 % |
Targeted Therapeutics in Non-Small Cell Lung Cancer
|
April 2007 |
£1325 |
14.7 % |
Drug Delivery in Cancer
Technologies, Markets and Companies
|
September 2008 |
£1605 |
12.5 % |
Supergen Inc
Premium Company Profile
|
December 2007 |
£265 |
11.5 % |
Hematological Cancer Therapeutics
Pipelines and Competition
|
September 2005 |
£2140 |
10.5 % |
Emerging Cancer Therapies
Markets and Business Opportunities
|
June 2002 |
£875 |
9.45 % |
Targeted Therapies in Oncology
A World Review
|
December 2006 |
£3360 |
8.4 % |
Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis
|
August 2008 |
£1540 |
8.05 % |
Decoding Big Pharmas R&D Strategy in Oncology
|
September 2007 |
£2495 |
8.05 % |
Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology
|
October 2006 |
£1325 |
8.05 % |
Breast Cancer Drug Pipeline Update 2006
|
May 2007 |
£1015 |
8 % |
Antibody Drug Target Atlas in Oncology
|
June 2007 |
£2330 |
8 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1665 |
7.7 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1665 |
7.7 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1665 |
7.7 % |
Decoding Big Pharma's R&D Strategy in Oncology
|
September 2007 |
£1665 |
7.7 % |
Bladder Cancer Drug Pipeline Update 2007
|
May 2007 |
£680 |
7.5 % |
CRC Drug Pipeline Update 2005
|
May 2007 |
£1015 |
7.5 % |
Pancreatic Cancer Drug Pipeline Update 2007
|
May 2007 |
£1015 |
7.5 % |
Brain Cancer Drug Pipeline Update 2007
|
May 2007 |
£1525 |
7.5 % |
Incyte Corporation
Premium Company Profile
|
April 2008 |
£265 |
7.5 % |
Prostate Cancer - A Therapeutic & Competitive Insight
Drug Pipeline Update 2007
|
May 2007 |
£1015 |
7.5 % |
Vascular Targeting and Anti-angiogenesis in Oncology
Drug Pipeline Update 2007
|
May 2007 |
£1015 |
7.5 % |
Fluorescence Lifetime Trends 2007
|
March 2007 |
£1540 |
7.35 % |
Inflammatory Disease Therapeutics
Pipelines and Competitive Dynamics
|
June 2005 |
£2140 |
7.35 % |
Sgx Pharmaceuticals Inc
Premium Company Profile
|
December 2007 |
£265 |
7 % |
Lung Cancer Drug Pipeline Update 2006
|
May 2007 |
£1015 |
7 % |
Pipeline Insight: Innovative Therapies
Targeted therapy, a clinical and commercial revolution?
|
August 2004 |
£6000 |
7 % |
Currently Druggable in Prostate Cancer
A Drug Target Competitive Analysis
|
September 2008 |
£1215 |
7 % |
Melanoma Drug Pipeline Update 2007
|
May 2007 |
£1015 |
7 % |
Apoptosis in Oncology
Drug Pipeline Update 2007
|
May 2007 |
£1015 |
7 % |
TR-FRET Based Assay Trends 2008
|
December 2007 |
£1540 |
7 % |
Non-Antibody Based Cancer Vaccines: Drug Pipeline Update 2006
Drug Pipeline Update 2007
|
May 2007 |
£1015 |
6.5 % |
Leukemia Drug Pipeline Update 2006
|
May 2007 |
£1015 |
6.5 % |
Hematological Cancers Drug Pipeline Update 2006
|
May 2007 |
£1355 |
6.5 % |
Renal Cancer Drug Pipeline Update 2007
|
May 2007 |
£1015 |
6.5 % |
Immunotherapy in Oncology
Drug Pipeline Update 2007
|
May 2007 |
£1355 |
6.5 % |
Ovarian Cancer Drug Pipeline Update 2007
|
May 2007 |
£1015 |
6.5 % |
Liver Cancer Drug Pipeline Update 2007
|
May 2007 |
£680 |
6 % |
Lymphoma Drug Pipeline Update 2006
|
May 2007 |
£1015 |
6 % |
Cancer Drug Resistance
2008
|
September 2008 |
£1675 |
5.95 % |
Lymphoma
A Therapeutic & Competitive Insight
|
May 2006 |
£1325 |
5.95 % |
Cardiovascular Molecular Imaging
|
July 2007 |
£130 |
5.6 % |
Cancer Vaccines: Aim and Shoot
|
May 2008 |
£1535 |
5.6 % |
New Concepts in Cancer Therapeutics
|
December 2005 |
£1665 |
5.25 % |
Hematological Cancers - A Therapeutic & Competitive Insight
|
October 2006 |
£2000 |
5.25 % |
Preclinical Cancer Therapeutics 2007
Decoding Next Generation Drug Targets for Market Success
|
December 2006 |
£1600 |
5.25 % |
Large Pharma:2004 a year of Progress
|
January 2005 |
£1325 |
4.9 % |
Prostate and Breast Cancer- New Treatments & Developmental Progress
|
March 2007 |
£2000 |
4.9 % |
Powering Discovery through Target Evaluation
Moving Beyond the Validation Paradigm
|
August 2005 |
£1950 |
4.9 % |
Promising Drug Discovery Tools in Antifungal & Status on Emerging Novel Targets
|
August 2004 |
£335 |
4.9 % |
Apoptosis: Promise or deception?
|
May 2005 |
£1325 |
4.55 % |
Innovations in Bioinformatics
Emerging Tools for Drug Discovery and Development
|
January 2008 |
£1995 |
4.55 % |
Antibodies in Oncology
Drug Pipeline Update 2007
|
May 2007 |
£1015 |
4.5 % |
Non-Small Cell Lung Cancer Drug Pipeline Update 2007
|
April 2007 |
£1015 |
4.5 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC
|
July 2007 |
£3510 |
4.5 % |
Global Pipeline Review & Analysis of Hematological Malignancies
|
March 2007 |
£1665 |
4.2 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
|
June 2007 |
£3510 |
4.2 % |
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Leukemias and Lymphomas
|
June 2007 |
£3510 |
4.2 % |
Drug Targets for Breast Cancer
|
January 2006 |
£1095 |
4 % |
Leukemia - A Therapeutic & Competitive Insight
|
October 2006 |
£1325 |
3.85 % |
Rheumatoid Arthritis: Emerging drug discovery targets
And therapeutic candidates
|
October 2003 |
£375 |
3.85 % |
Breast Cancer
The Latest R&D Trends
|
February 2007 |
£1325 |
3.85 % |
Model Animal Systems
Emerging Applications and Commercial Opportunities in Drug Discovery and Development
|
June 2004 |
£1946 |
3.85 % |
Pipeline Insight: Molecular Targeted Cancer Therapies Can anything else revolutionize the market?
- Cancer
|
October 2007 |
£7600 |
3.5 % |
Alzheimer disease
new drugs, markets and companies
|
September 2008 |
£1500 |
3.5 % |
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer
|
March 2006 |
£2340 |
3.5 % |
China Medical Technologies, Inc. Product Pipeline Analysis
|
August 2008 |
£400 |
3.5 % |
Monoclonal Antibodies, Vaccines and Other Immunologic Cancer Treatments
World Market
|
May 2007 |
£1005 |
3.15 % |
Cardiovascular Diagnostics
Key Developments in Technologies and Markets
|
May 2005 |
£1950 |
3.15 % |
Innovations in The Management of Diabetes
Next generation treatments and market dynamics
|
June 2008 |
£1995 |
3.15 % |
Rheumatoid Arthritis: Market Trends and R&D Insights
|
September 2006 |
£620 |
3.15 % |
Competitive Outlook on Apoptosis in Oncology
|
December 2006 |
£1325 |
3.15 % |
Analysis of the Pharmaceutical Market to 2012 - Segmented by Drug Target Family
Sales & Marketing
|
October 2007 |
£3800 |
2.8 % |
Drug Discovery Handbook
|
July 2005 |
£94.5 |
2.8 % |
Proteomics
Technologies, Markets and Companies
|
September 2008 |
£1875 |
2.8 % |
Top 7 Cancer Indications
Therapeutic & Competitive Insights
|
January 2007 |
£4715 |
2.8 % |
Stakeholder Opinions: Percutaneous Coronary Intervention
Adverse events with drug-eluting stents demand a new safety standard
|
April 2008 |
£2000 |
2.8 % |
Immunomodulators
Therapeutic Needs, Pipelines & Prospects
|
August 2007 |
£1495 |
2.45 % |
Innovative And Targeted Cancer Therapies
Key Technologies, New Applications And Leading Players
|
July 2007 |
£1545 |
2.45 % |
Cancer Antibodies
Competitive Positioning for Success
|
June 2008 |
£1535 |
2.1 % |
Stakeholder Opinions: Hepatocellular Carcinoma
Opportune indication for novel therapies
|
June 2007 |
£2000 |
2.1 % |
High Throughput Screening
|
January 2008 |
£1525 |
2.1 % |
Stakeholder Opinions: Chronic Leukemias
Curative Intent Raises the Bar
|
October 2005 |
£2195 |
2.1 % |
Novel Targets in Drug Discovery
A new era in therapy
|
April 2004 |
£595 |
2.1 % |
The Autoimmune Inflammatory Bowel Disease Market Outlook to 2012
|
February 2007 |
£1499 |
2.1 % |
The Medical Device Market: South Africa
|
December 2007 |
£595 |
2.1 % |
World Neurodegeneratives Disease Markets
|
February 2005 |
£1499 |
1.75 % |
Organ Transplant Immunosuppressive Markets
|
January 2008 |
£1765 |
1.75 % |
Stakeholder Opinions: Melanoma
Lucrative commercial opportunities persist
|
December 2006 |
£2000 |
1.75 % |
Pipeline Insight: Disease Modification In Rheumatoid Arthritis
Pipeline Uptake Inhibited By Anti-TNFs
|
October 2005 |
£6495 |
1.75 % |
Triple Analysis: Apoptosis Agents, Antibodies and Vaccines in Oncology
|
December 2006 |
£2340 |
1.75 % |
The Top 10 Biotechnology Companies
|
January 2005 |
£1495 |
1.75 % |
Chemotherapy Market Insights, 2006-2016
A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
|
April 2006 |
£1900 |
1.75 % |
Commercial Opportunities from Biomarkers
Transforming drug discovery, clinical development and molecular diagnostic
|
May 2006 |
£1495 |
1.75 % |
Drug Discovery
Current trends and future prospects
|
February 2001 |
£300 |
1.75 % |
Pipeline Insight: Non-Small Cell Lung Cancer
Pipeline set to offer only modest improvements
|
April 2008 |
£6000 |
1.4 % |
Pipeline Insight: Antithrombotics
Anticoagulants and Antiplatelets Have Blockbuster Potential
|
October 2005 |
£6495 |
1.4 % |
Personalized Medicine
scientific & commercial aspects
|
September 2008 |
£2140 |
1.4 % |
Cancer Therapeutics: The Worldwide Market
The Worldwide Market , 2nd Editon
|
February 2007 |
£2015 |
1.4 % |
Monoclonal Antibodies Report
|
June 2008 |
£3800 |
1.4 % |
Companion Diagnostics in Personalized Medicine and Cancer Therapy
|
April 2008 |
£1715 |
1.4 % |
Pipeline Insight: Non-insulin antidiabetics Incretin mimetics leaders in a diverse pipeline
|
May 2008 |
£6000 |
1.4 % |
Stakeholder Opinions: Acute Leukemias
Persistent unmet needs confer significant commercial opportunity
|
April 2006 |
£2170 |
1.4 % |
Nitric Oxide
Therapeutics, Markets and Companies
|
September 2008 |
£1500 |
1.4 % |
RNAi
Technologies, Markets and Companies
|
September 2008 |
£1605 |
1.4 % |
ADME/TOX Technologies
|
January 2008 |
£1450 |
1.4 % |
Stakeholder Insight: Non-Small Cell Lung Cancer
The need for greater product differentiation in an increasingly crowded market
|
November 2006 |
£8000 |
1.05 % |
Neurogenomics and Neurotherapeutic Strategies
New Directions in Platforms, Targets, and Therapeutic Approaches
|
February 2005 |
£1950 |
1.05 % |
Apoptosis
|
January 2008 |
£1440 |
1.05 % |
The Global Market for Advanced Wound Care Products 2007
|
March 2007 |
£695 |
1.05 % |
Drug Delivery in Central Nervous System Diseases
technologies,markets and companies
|
September 2008 |
£1340 |
1.05 % |
Antiviral Therapeutics
Technologies, Markets and Companies
|
September 2008 |
£1500 |
1.05 % |
Antibiotics and Drug Resistance 2008
Drug Innovation and the Strategy to Combat - Antibiotic Resistance Mechanisms
|
January 2008 |
£1499 |
1.05 % |
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007
|
June 2007 |
£1999 |
1.05 % |
Metabolomics
|
January 2008 |
£1370 |
1.05 % |
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies
More drugs on the market, more targets in the pipeline
|
October 2006 |
£8000 |
0.7 % |
Pain Therapeutics
Drugs, Markets and Companies
|
September 2008 |
£1605 |
0.7 % |
Global Market for Advanced Wound Care Products 2008, The
A complete review of this fast growing, highly innovative sector
|
April 2008 |
£695 |
0.7 % |
|
|
|
|
